vs
安进（AMGN）与CDW Corporation（CDW）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是CDW Corporation的1.8倍（$9.9B vs $5.5B），安进同比增速更快（8.6% vs 6.3%），安进自由现金流更多（$961.0M vs $395.9M），过去两年安进的营收复合增速更高（15.1% vs 6.3%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
CDW公司是美国多品牌信息技术服务提供商，服务覆盖美国、英国、加拿大三国的商业、政府、教育、医疗领域，总部位于伊利诺伊州弗农希尔斯，位列《财富》500强，2023年全年净销售额达210亿美元。
AMGN vs CDW — 直观对比
营收规模更大
AMGN
是对方的1.8倍
$5.5B
营收增速更快
AMGN
高出2.3%
6.3%
自由现金流更多
AMGN
多$565.1M
$395.9M
两年增速更快
AMGN
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $5.5B |
| 净利润 | $1.3B | — |
| 毛利率 | 69.8% | 22.8% |
| 营业利润率 | 27.6% | 7.8% |
| 净利率 | 13.5% | — |
| 营收同比 | 8.6% | 6.3% |
| 净利润同比 | 112.6% | — |
| 每股收益（稀释后） | $2.45 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNCDW
| Q4 25 | $9.9B | $5.5B | ||
| Q3 25 | $9.6B | $5.7B | ||
| Q2 25 | $9.2B | $6.0B | ||
| Q1 25 | $8.1B | $5.2B | ||
| Q4 24 | $9.1B | $5.2B | ||
| Q3 24 | $8.5B | $5.5B | ||
| Q2 24 | $8.4B | $5.4B | ||
| Q1 24 | $7.4B | $4.9B |
净利润AMGNCDW
| Q4 25 | $1.3B | — | ||
| Q3 25 | $3.2B | $291.0M | ||
| Q2 25 | $1.4B | $271.2M | ||
| Q1 25 | $1.7B | $224.9M | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $2.8B | $316.4M | ||
| Q2 24 | $746.0M | $281.1M | ||
| Q1 24 | $-113.0M | $216.1M |
毛利率AMGNCDW
| Q4 25 | 69.8% | 22.8% | ||
| Q3 25 | 67.8% | 21.9% | ||
| Q2 25 | 67.2% | 20.8% | ||
| Q1 25 | 63.6% | 21.6% | ||
| Q4 24 | 65.7% | 22.3% | ||
| Q3 24 | 61.1% | 21.8% | ||
| Q2 24 | 61.4% | 21.8% | ||
| Q1 24 | 57.0% | 21.8% |
营业利润率AMGNCDW
| Q4 25 | 27.6% | 7.8% | ||
| Q3 25 | 26.4% | 7.7% | ||
| Q2 25 | 28.9% | 7.0% | ||
| Q1 25 | 14.5% | 7.0% | ||
| Q4 24 | 25.4% | 7.9% | ||
| Q3 24 | 24.1% | 8.7% | ||
| Q2 24 | 22.8% | 8.0% | ||
| Q1 24 | 13.3% | 6.7% |
净利率AMGNCDW
| Q4 25 | 13.5% | — | ||
| Q3 25 | 33.7% | 5.1% | ||
| Q2 25 | 15.6% | 4.5% | ||
| Q1 25 | 21.2% | 4.3% | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 33.3% | 5.7% | ||
| Q2 24 | 8.9% | 5.2% | ||
| Q1 24 | -1.5% | 4.4% |
每股收益（稀释后）AMGNCDW
| Q4 25 | $2.45 | $2.13 | ||
| Q3 25 | $5.93 | $2.21 | ||
| Q2 25 | $2.65 | $2.05 | ||
| Q1 25 | $3.20 | $1.69 | ||
| Q4 24 | $1.17 | $1.97 | ||
| Q3 24 | $5.22 | $2.34 | ||
| Q2 24 | $1.38 | $2.07 | ||
| Q1 24 | $-0.21 | $1.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $618.7M |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | $2.6B |
| 总资产 | $90.6B | $16.0B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNCDW
| Q4 25 | $9.1B | $618.7M | ||
| Q3 25 | $9.4B | $452.9M | ||
| Q2 25 | $8.0B | $481.0M | ||
| Q1 25 | $8.8B | $688.1M | ||
| Q4 24 | $12.0B | $717.7M | ||
| Q3 24 | $9.0B | $1.2B | ||
| Q2 24 | $9.3B | $665.3M | ||
| Q1 24 | $9.7B | $803.8M |
总债务AMGNCDW
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNCDW
| Q4 25 | $8.7B | $2.6B | ||
| Q3 25 | $9.6B | $2.5B | ||
| Q2 25 | $7.4B | $2.5B | ||
| Q1 25 | $6.2B | $2.3B | ||
| Q4 24 | $5.9B | $2.4B | ||
| Q3 24 | $7.5B | $2.3B | ||
| Q2 24 | $5.9B | $2.2B | ||
| Q1 24 | $5.0B | $2.1B |
总资产AMGNCDW
| Q4 25 | $90.6B | $16.0B | ||
| Q3 25 | $90.1B | $15.2B | ||
| Q2 25 | $87.9B | $15.3B | ||
| Q1 25 | $89.4B | $15.0B | ||
| Q4 24 | $91.8B | $14.7B | ||
| Q3 24 | $90.9B | $14.4B | ||
| Q2 24 | $90.9B | $13.6B | ||
| Q1 24 | $93.0B | $13.2B |
负债/权益比AMGNCDW
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $433.8M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $395.9M |
| 自由现金流率自由现金流/营收 | 9.7% | 7.2% |
| 资本支出强度资本支出/营收 | 6.5% | 0.7% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | $1.1B |
8季度趋势，按日历期对齐
经营现金流AMGNCDW
| Q4 25 | $1.6B | $433.8M | ||
| Q3 25 | $4.7B | $328.3M | ||
| Q2 25 | $2.3B | $155.9M | ||
| Q1 25 | $1.4B | $287.2M | ||
| Q4 24 | $4.8B | $345.3M | ||
| Q3 24 | $3.6B | $342.1M | ||
| Q2 24 | $2.5B | $149.9M | ||
| Q1 24 | $689.0M | $440.0M |
自由现金流AMGNCDW
| Q4 25 | $961.0M | $395.9M | ||
| Q3 25 | $4.2B | $298.5M | ||
| Q2 25 | $1.9B | $133.4M | ||
| Q1 25 | $980.0M | $260.3M | ||
| Q4 24 | $4.4B | $316.7M | ||
| Q3 24 | $3.3B | $308.5M | ||
| Q2 24 | $2.2B | $119.0M | ||
| Q1 24 | $459.0M | $410.5M |
自由现金流率AMGNCDW
| Q4 25 | 9.7% | 7.2% | ||
| Q3 25 | 44.4% | 5.2% | ||
| Q2 25 | 20.8% | 2.2% | ||
| Q1 25 | 12.0% | 5.0% | ||
| Q4 24 | 48.4% | 6.1% | ||
| Q3 24 | 39.0% | 5.6% | ||
| Q2 24 | 26.5% | 2.2% | ||
| Q1 24 | 6.2% | 8.4% |
资本支出强度AMGNCDW
| Q4 25 | 6.5% | 0.7% | ||
| Q3 25 | 4.6% | 0.5% | ||
| Q2 25 | 4.0% | 0.4% | ||
| Q1 25 | 5.0% | 0.5% | ||
| Q4 24 | 4.1% | 0.6% | ||
| Q3 24 | 3.0% | 0.6% | ||
| Q2 24 | 2.8% | 0.6% | ||
| Q1 24 | 3.1% | 0.6% |
现金转化率AMGNCDW
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | 1.13× | ||
| Q2 25 | 1.59× | 0.57× | ||
| Q1 25 | 0.80× | 1.28× | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | 1.08× | ||
| Q2 24 | 3.30× | 0.53× | ||
| Q1 24 | — | 2.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
CDW
暂无分部数据
